We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab (Takhzyro) and soon HAE patients in Quebec will have access to Takhzyro. When we learn exactly when the treatment will be accessible, we will be sure to share it here, on our website.
To help INESSS make an informed decision, in December 2019 HAE Canada submitted Patient Input for Lanadelumab (Takhzyro): Drug Evaluation Questionnaire for Patient and Caregiver Associations and Groups. This document references HAE Canada’s submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review (CDR) Pharmacoeconomic review report – Lanadelumab (Takhzyro).